(E)-2-(3-Chlorostyryl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 95.0%, 250mg

(1S)-((2R,4S,5R)-5-Ethylquinuclidin-2-yl)(6-methoxyquinolin-4-yl)methanol, 95.0%, 5g

2-(2-Cyclobutyl-4-fluoro-1H-1,3-benzodiazol-1-yl)acetic acid, 1g

2,3-Diaminopyridine, 95.0%, 10g

1-methyl-3-nitro-1H-1,2,4-triazole, 95%, 10g

3-(Hydroxyimino)pentane-2,4-dione, 97+%, 100mg

HBTU [Coupling Reagent for Peptide]>98.0%(HPLC)25g

1-(3-Bromo-2-hydroxyphenyl)ethanone, 95.0%, 5g

(3-Methylphenyl)(2,4,6-trimethylphenyl)iodoniumTrifluoromethanesulfonate, 98%, 25g

1-((4S,5S)-2,2-dimethyl-5-vinyl-1,3-dioxolan-4-yl)-2-(trityloxy)ethanone, 98%, 1g

Methyl 5-bromo-6-oxo-1,6-dihydropyridazine-3-carboxylate, 98%, 1g

(3,5-Dimethoxyphenyl)acetic acid ethyl ester, 95.0%, 25g

N-([1,1'-Biphenyl]-2-yl)-9,9-dimethyl-9H-fluoren-3-amine, 97%, 1g